Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase

Journal of Medicinal Chemistry

Volumn 41, Issue 22, 1998, Pages 4288-4300

  Augeri, David J ^a   O'Connor, Stephen J ^a   Janowick, Dave ^a   Szczepankiewicz, Bruce ^a   Sullivan, Gerry ^a   Larsen, John ^a   Kalvin, Douglas ^a   Cohen, Jerry ^a   Devine, Edward ^a   Zhang, Haichao ^a   Cherian, Sajeev ^a   Saeed, Badr ^a   Ng, Shi Chung ^a   Rosenberg, Saul ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PYRIDYLOXYMETHYL) 2 (2 METHYLPHENYL)BENZOYLMETHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG POTENCY; DRUG POTENTIATION; DRUG TRANSFORMATION; ENZYME INHIBITION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; CATTLE; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; METHIONINE; MICE; PROTEIN ISOPRENYLATION; PYRIDINES; RAS PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15144355763     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980298s     Document Type: Article

References (31)

1. Barbacid, M. Ras Genes. Annu. Rev. Biochem. 1987, 56, 779.
2. Bos, J. L. ras Oncogenes in Human Cancer: A Review. Cancer Res. 1989, 49, 4682-4689.
3. Cox, A. D.; Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1997, 1333, F51-71.
4. Casey, P. J.; Solski, P. A.; Der, C. I.; Buss, J. E. p21 Ras is Modified by a Farnesyl Isoprenoid Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8223.
5. Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell Biol. 1992, 4, 1008-16.
6. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-77.
7. Newman, C. M.; Magee, A. I. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim. Biophys. Acta 1993, 1155, 79-96.
8. Schafer, W. R.; Rine, J. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 1992, 26, 209-37.
9. Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Chemotherapeutic. Cell 1994, 77, 175.
10. Gibbs, J. B.; Oliff, A. The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 143-166.
11. Singh, S. B.; Lingham, R. B. Farnesyl-Protein Transferase Inhibitors in Early Development, Exp. Opin. Invest. Drugs 1996, 5, 1589-1599.
12. Orner, C. A.; Kohl, N. E. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends Pharmacol. Sci. 1997, 18, 437-44.
13. Leonard, D. M. Ras Farnesyltransferase; A New Therapeutic Target. J. Med. Chem. 1997, 40, 2971-2990.
14. Mallams, A. K., Rossman, R. R.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K.; Petrin, J.; Wang, L.; Patton, R.; Bishop, W. R.; Carr, D. M.; Kirschmeier, P.; Catino, J. J.; Bryant, M. S.; Chen, K.-J.; Korfmacher, W. A.; Nardo, C.; Wang, S.; Nomeir, A. A.; Lin, C.-C.; Li, Z.; C Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chlpro-6,11-dihydro-5H-benzo[5.6] cyclohepta[1,2-6]pyridin-11-yl)piperazineand (1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. J. Med. Chem, 1998, 47, 877.
15. Njoroge, F. G.; Vibulbhan, B.; Rane, D. F.; Bishop, W. R.; Petrin, J.; Patton, R.; Bryant, M. S.; Chen, K.-J.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Structure-Activity Relationship of 3-Substituted N-(Pyi-idinylacetyl)-4-(8-chloro-5,6-dihydro-11H-(benzo[5,6]cyclohepta[1,2-6] pyridin-11-ylidene)-piperidine Inhibitors of Farnesy-Protem Transferase: Design and Synthesis of in-Vivo Active Antitumor Compounds. J. Med. Chem. 1997, 40, 4290-4301.
16. Leftheris, K.; Kline, T.; Vite, G. D.; Cho, Y. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weiler, H. N.; Andahazy, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity J. Med. Chem. 1996, 39, 224-236.
17. Sebti, S. M.; Hamilton, A. D. New Approaches to Anticancer Drug Design Based on the Inhibition of Farnesyltransferase. DDT 1998, 3, 26-33.
18. Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; S. J., d.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein Farnesyltransferase Inhibitors Block the Growth of Ras-Dependent Tumors in Nude Mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 92, 9141.
19. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. T.; McDowell, R. S.; Crowley, C.; Lucas, B.; Levinson, A.; Marsters, J. C. Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells. Science 1993, 260, 1937.
20. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
21. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deanna, A. A.; Garsky, V. M.; Scholtz, T. H.; J. B., G.; Smith, R. L. Pseudopeptide Inhibitors of Ras Farnseyl-protein Transferase. J. Med. Chem. 1994, 37, 725.
22. deSolms, S. J.; Deana, A. A.; Giuliani, E. A.; Graham, S. L.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Scholtz, T. H.; Wiggins, J. M.; Gibbs, J. B.; Smith, R. L. Pseudopeptide Inhibitors of Protein Farnesyltransferase. J. Med. Chem. 1995, 35, 3967-3971.
23. Burns, C. J. Guitton, J.-D.; Baudoin, B.; Lelievre, Y.; Duchesne, M.; Parker, F.; Fromage, N.; Commercon, A. Novel Conformationally Extended Naphthalene-Based Inhibitors of Farnesyltransferase J. Med. Chem. 1997, 40, 1763-1767.
24. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma With K-Ras Mutation and p53 Deletion, Cancer Res. 1995, 55, 4243-4247.
25. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors. J. Med. Chem. 1996, 39, 217-223.
26. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 1995, 270, 26802-6.
27. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995,95, 2457.
28. Wang, S.-S. p-Alkoxybenzyl alcohol resin and p-alkoxybenzyloxycarbonylhydrazide resin for solid phase synthesis of protected peptide fragments. J. Am. Chem. Soc. 1972, 95, 1328.
29. Mancuso, A. J.; Huang, S.-L.; Swern, D. Oxidation of Long-Chain and Related Alcohols to Carbonyls by Dimethyl Sulfpxide "Activated" by Oxalyl Chloride. J. Org. Chem. 1978, 43, 2480.
30. Newman, M. S.; Karnes, H. A. Conversion of Phenols to Thiophenols via Dialkylthiocarbamates. J. Org. Chem. 1966, 31, 3980.
31. Patel, D. V.; Mine, T. B.; Meyers, C. A.; Leftheris, K.; Bhide, R. S. Preparation of Peptide Analog Inhibitors of Protein Farnesyltranfiferase; Patel, D. V., Kline, T. B., Meyers, C. A., Leftheris, K., Bhide, R. S., Eds.; Bristol-Myers Squibb: Princeton, NJ, 1994.